Ligand Pharmaceuticals Inc. Contingent Value Right (LGNDZ)

Overview

Ligand Pharmaceuticals Incorporated is a leading biopharmaceutical company, based in Jupiter, Florida, specializing in the development and licensing of innovative biopharmaceutical assets on a global scale. With a foundation laid in 1987, the company has established a significant presence in the medical and healthcare sector through its strategic alliances, licenses, and business relationships with major industry players such as Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Furthermore, Ligand Pharmaceuticals offers a unique product, Captisol materials, enhancing its portfolio and market reach. The company’s purpose revolves around addressing complex medical conditions by providing advanced therapeutic solutions and contributing to the improvement of patients' lives worldwide.

Products and Services

• Kyprolis & Evomela: These products are primarily used in the treatment of multiple myeloma, a type of cancer that affects the plasma cells in the blood.
• Rylaze: A recombinant erwinia asparaginase product designed for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in both adult and pediatric patients.
• Filspari: Currently in development, Filspari is a dual endothelin and angiotensin II receptor antagonist intended for rare kidney diseases and serves as a non-immunosuppressive treatment for immunoglobulin A nephropathy.
• Teriparatide Injection: An injectable osteoporosis treatment that is designed to decrease the risk of fracture by stimulating bone formation.
• Vaxneuvance & Pneumosil: These vaccinal solutions target the prevention of invasive diseases caused by various serotypes of streptococcus pneumoniae, largely focusing on combating pneumococcal pneumonia among children.
• TZIELD: A CD3-directed antibody indicated to delay the onset of Stage 3 Type 1 Diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D.
• Nexterone: A captisol-enabled formulation of amiodarone, offering a novel delivery method for this critical antiarrhythmic medication.
• Zulresso: A captisol-enabled formulation of brexanolone, Zulresso is a pioneering treatment for postpartum depression.
• Veklury: An antiviral treatment designed for moderate or severe COVID-19, showcasing the company's versatility in addressing emergent global health crises.
• Noxafil-IV: A captisol-enabled formulation of posaconazole for IV use, providing a critical solution for fungal infections.
• Duavee: Developed for the treatment of post-menopausal symptoms in women, offering relief and support during the menopausal transition.
• Exemptia, Vivitra, Bryxta, and Zybev: Targeting various indications, these products are part of the company’s expansive portfolio aimed at addressing autoimmune diseases, breast cancer, and more, showcasing Ligand Pharmaceuticals’ commitment to diverse therapeutic areas.